Mikhail Regelman, MD
Urology · Woodbury, MNNPI 1891015384
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (34.5%), education and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Intuitive Surgical at 37.7% of the total.
Across 140 payments — averaging $71.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Sanofi$2K
- Blue Earth Diagnostics$934
- Sumitomo Pharma America, Inc.$502
- Urovant Sciences Inc$484
- Dendreon Pharmaceuticals LLC$394
- plus $2K from 22 others
What the payments were for
- Consulting fees$2,92729%
- Travel & lodging$6066%
- Food & beverage$3,43534%
- Education$3,00030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $3,758 |
| Sanofi | 2 | $2,188 |
| Blue Earth Diagnostics | 4 | $934 |
| Sumitomo Pharma America, Inc. | 21 | $502 |
| Urovant Sciences Inc | 17 | $484 |
| Dendreon Pharmaceuticals LLC | 20 | $394 |
| Johnson & Johnson | 7 | $282 |
| AbbVie | 6 | $207 |
| Endo Pharmaceuticals Inc. | 9 | $191 |
| Urogen Pharma, Inc. | 4 | $108 |
| Astellas Pharma US Inc | 5 | $108 |
| Antares Pharma, Inc. | 5 | $96 |
| Janssen Scientific Affairs, LLC | 1 | $94 |
| Pfizer | 4 | $87 |
| Accord Healthcare, Inc. | 3 | $85 |
| Endo USA, Inc. | 3 | $65 |
| Amgen | 2 | $61 |
| Bayer | 2 | $59 |
| Procept Biorobotics Corporation | 2 | $49 |
| Merck | 2 | $42 |
| Davol Inc. | 1 | $34 |
| Tolmar, Inc. | 1 | $28 |
| Coloplast | 1 | $25 |
| Photocure Inc | 1 | $20 |
| Olympus America Inc. | 1 | $18 |
| KARL Storz Endoscopy-america | 1 | $17 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
| 180 Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$3,000
- JEVTANA$2,188
- Axumin$875
- Da Vinci Surgical System$587
- Erleada$133
How this compares
$9,968 in reported general payments places this provider in the 85th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 13 | $186,695 |
| MyrbetriqMirabegron | 122 | $98,639 |
| GemtesaVibegron | 74 | $57,202 |
| Tamsulosin Hcl | 624 | $11,400 |
| Solifenacin Succinate | 138 | $6,121 |
| Tadalafil | 41 | $6,003 |
| Finasteride | 337 | $4,784 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 130 | $3,188 |
| Dutasteride | 25 | $1,778 |
| Silodosin | 17 | $1,441 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $1,194 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 89 | $710 |
| Cephalexin | 90 | $605 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $535 |
| Imipramine Hcl | 12 | $344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $108 | $285,334135 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $502 | $57,20274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 urology providers in Minnesota.
Other urology in Woodbury
- Steven SiegelWoodbury$140K
- Aaron MilbankWoodbury$97K
- Spencer HartWoodbury$69K
- Jodi MichaelsWoodbury$66K
- Anthony PolcariWoodbury$7K
- Samuel KieleyWoodbury$6K
- David YangMankato$298K
- Steven BernsteinEdina$271K
- Ayman SoubraMinneapolis$204K
- Sean ElliottMinneapolis$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.